Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.
Alexandra LebedevaEgor VeselovskyAlexandra KavunEkaterina BelovaTatiana GrigorevaPavel OrlovAnna SubbotovskayaMaksim ShipunovOleg MashkovFanil BilalovPeter ShatalovAndrey KaprinPeter ShegaiZhan DiuzhevOchir MigiaevNatalya VytnovaVladislav MileykoMaxim IvanovPublished in: World journal of oncology (2024)
predictions of the observed HRR gene variants suggest that non-BRCA gene testing is likely to result in higher frequency of patients who are candidates for PARP inhibitor therapy. Continuing sequencing efforts should clarify interpretation of frequently observed non-BRCA VUS.
Keyphrases
- copy number
- dna damage
- dna repair
- end stage renal disease
- ejection fraction
- genome wide
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- genome wide identification
- single cell
- dna methylation
- gene expression
- climate change
- patient reported outcomes
- quality improvement
- patient reported
- breast cancer risk
- bone marrow
- human health
- structural basis
- genome wide analysis